Colobreathe (colistimethate sodium dry powder inhalation) / Teva, Essential Pharma - LARVOL DELTA

A review of prescribed inhaled antibiotic trials in a single adult cystic fibrosis center pre and post elexacaftor/tezacaftor/ivacaftor (NACFC 2025) - "There was a decline in the number of trials completed in the majority of inhaled antibiotics with the exception of Tobramycin (no change from n = 4); Amikacin liposome and Meropenem had an increase in trials (both n = 1). Tobramycin Tobi Podhaler® had the most drop in number (n = 85), followed by Tobramycin Bramitob® (n = 50), Colistimethate Sodium dry powder Colobreathe® (n = 33), Colistin (n = 32), Aztreonam lysine (n = 12), and Levofloxacin (n = 3) (Figure 1)... 1. The number of inhaled antibiotic trials in our adult CF Center has declined post ETI therapy. 2."

Clinical • Review • Cystic Fibrosis • Genetic Disorders • Immunology • Respiratory Diseases

Medicines optimisation: Using adherence to support supply (ECFS 2024) - "The most cost savings were generated from Cayston nebuliser, this could be because it is one of the more expensive nebuliser treatments equating to £2,181.53 for a month's supply... The enhanced role of the pharmacy technician reduces the burden of work from the multidisciplinary team. Pharmacy technicians are ideally placed to carry out homecare prescription reviews and cost saving exercises. As this project has shown, many substantial cost savings and optimisation come with nebuliser treatments."

Adherence

Essential Pharma acquires European rights to Colobreathe (colistimethate sodium) from Teva (BioSpace) - "Essential Pharma....announces that it has completed the acquisition of European rights to Colobreathe^® from Teva Laboratories UK Limited. Colobreathe^® is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa (PsA) in patients with cystic fibrosis aged 6 years and older....Under the terms of the acquisition, Essential Pharma has acquired the rights to Colobreathe^® across European markets; the product is currently marketed across more than 20 countries in Europe, including the UK."

M&A • Cystic Fibrosis